ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition

BACKGROUND: Prolactin receptor (PRLR) is an attractive antibody therapeutic target with expression across a broad population of breast cancers. Antibody efficacy, however, may be limited to subtypes with either PRLR overexpression and/or those where estradiol no longer functions as a mitogen and are...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Mark G., Zhang, Qian, Rodriguez, Luis E., Hecquet, Claudie M., Donawho, Cherrie K., Ansell, Peter J., Reilly, Edward B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191021/
https://www.ncbi.nlm.nih.gov/pubmed/34107902
http://dx.doi.org/10.1186/s12885-021-08403-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191021/
https://www.ncbi.nlm.nih.gov/pubmed/34107902
http://dx.doi.org/10.1186/s12885-021-08403-5

Ejemplares similares